Want to join the conversation?
In Oct. 2015, $LLY acquired the worldwide rights to Canadian firm Locemia Solutions' intranasal glucagon, a glucagon nasal powder being investigated for the treatment for severe hypoglycemia. Upon entry into the agreement, $LLY paid approx. $150MM, which will be accounted for in the fourth quarter of 2015.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.